Occidental: OxyChem Sale, Q4 Beat, Shares Rise Now

Occidental: OxyChem Sale, Q4 Beat, Shares Rise Now

Introduction

Occidental Petroleum (OXY) delivered a string of tangible developments this week that materially affect investors: a solid fourth-quarter performance, the closing of the OxyChem divestiture, a clearer path to deleveraging, and a dividend increase. Those outcomes—not speculation—drove heavy volume, a jump in the share price and a new 52‑week high. This article summarizes the events, the numbers behind them, and what they mean for shareholders looking for capital returns and balance-sheet improvement.

What Happened: Concrete Events and Results

Q4 earnings beat and operational performance

Occidental reported adjusted earnings per share of $0.31 for Q4, ahead of consensus estimates. Revenue landed at roughly $5.11 billion, slightly below some forecasts, but production and cash generation were the stronger story. The company recorded record production near 1,481 thousand barrels of oil equivalent per day (Mboed) and generated about $1.0 billion in free cash flow before working capital effects. Those operational metrics offset the revenue miss and signaled execution across upstream and midstream assets.

Balance-sheet progress: OxyChem sale completed

Occidental closed the sale of its OxyChem chemical business, realizing approximately $9.7 billion in cash. Management used proceeds to retire principal debt and reduce total debt to roughly $15 billion. That deleveraging milestone is material: it aligns with previously stated targets and improves financial flexibility, including the potential to return capital to shareholders once leverage metrics permit.

Capital Allocation and Guidance

Lower CapEx and a higher dividend

For 2026 Occidental guided lower capital expenditures—roughly $5.5–$5.9 billion—demonstrating disciplined spending aligned with higher free cash flow generation. At the same time, the company announced an 8%+ increase in its quarterly dividend to $0.26 per share. The combination of disciplined CapEx and a raised dividend signals a shift toward predictable cash returns alongside balance-sheet repair.

Shareholder returns and potential buybacks

With debt now near the company’s target range, management reiterated that share repurchases could resume once leverage thresholds are sustainably met. The OxyChem proceeds accelerate that timeline relative to prior expectations and explain the market’s renewed appetite for OXY equity.

Market Reaction and What the Data Shows

Following the earnings release and the confirmed divestiture, OXY shares climbed to a 52‑week high and saw several days of above-average trading volume—indicating broad participation from institutional and retail investors. The stock’s movement was supported by concrete balance-sheet improvement and clearer visibility on capital allocation, rather than speculative headlines.

Analyst context and valuation caution

Analysts responded with mixed reactions: some raised targets and ratings on the improved leverage profile and cash-flow outlook, while others cautioned that OXY’s valuation now embeds higher expectations. Key risk remains commodity-price sensitivity—sustained free cash flow depends on oil and gas realizations even after operational wins.

Conclusion

This week’s developments for Occidental are notable because they are measurable and impactful: a completed $9.7 billion OxyChem sale, a reduction in debt to about $15 billion, a Q4 adjusted EPS beat ($0.31), roughly $1.0 billion in operating free cash flow, lower 2026 CapEx guidance ($5.5–$5.9 billion), and a raised quarterly dividend to $0.26 per share. Together, these elements tightened the path to resumed buybacks and improved financial optionality. Investors should balance the improved capital-return potential and stronger balance sheet against ongoing commodity cyclicality and relative valuation levels when re-assessing OXY exposure.

Data points referenced are from Occidental’s recent public disclosures and trading activity during the February 18–23, 2026 timeframe.